Precision Biosciences Inc (DTIL)

$10.72

-0.79

(-6.86%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Precision Biosciences Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 19.78M → 7.03M (in $), with an average decrease of 40.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -8.07M → -16.28M (in $), with an average decrease of 101.6% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 104.5%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 340.7%

Performance

  • $10.70
    $11.63
    $10.72
    downward going graph

    0.19%

    Downside

    Day's Volatility :8.0%

    Upside

    7.82%

    downward going graph
  • $8.25
    $28.44
    $10.72
    downward going graph

    23.04%

    Downside

    52 Weeks Volatility :70.99%

    Upside

    62.31%

    downward going graph

Returns

PeriodPrecision Biosciences IncSector (Health Care)Index (Russel 2000)
3 Months
1.8%
-0.7%
0.0%
6 Months
24.45%
6.6%
0.0%
1 Year
-57.76%
3.7%
-1.5%
3 Years
-95.28%
14.0%
-21.8%

Highlights

Market Capitalization
89.0M
Book Value
$4.53
Earnings Per Share (EPS)
-332.12
Wall Street Target Price
35.8
Profit Margin
-125.84%
Operating Margin TTM
-211.57%
Return On Assets TTM
-13.74%
Return On Equity TTM
-107.26%
Revenue TTM
48.7M
Revenue Per Share TTM
12.69
Quarterly Revenue Growth YOY
-33.6%
Gross Profit TTM
25.1M
EBITDA
-36.9M
Diluted Eps TTM
-332.12
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-7.4
EPS Estimate Next Year
-4.67
EPS Estimate Current Quarter
-2.05
EPS Estimate Next Quarter
-2.11

Analyst Recommendation

Buy
    81%Buy
    18%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Precision Biosciences Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
10
10
Hold
2
2
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 233.96%

Current $10.72
Target $35.80

Company Financials

FY18Y/Y Change
Revenue
10.9M
↑ 67.84%
Net Income
-46.0M
↑ 118.16%
Net Profit Margin
-423.02%
↓ 97.57%
FY19Y/Y Change
Revenue
22.2M
↑ 104.34%
Net Income
-83.3M
↑ 80.94%
Net Profit Margin
-374.59%
↑ 48.43%
FY20Y/Y Change
Revenue
24.3M
↑ 9.2%
Net Income
-109.0M
↑ 30.86%
Net Profit Margin
-448.86%
↓ 74.27%
FY21Y/Y Change
Revenue
115.5M
↑ 375.72%
Net Income
-30.9M
↓ 71.64%
Net Profit Margin
-26.76%
↑ 422.1%
FY22Y/Y Change
Revenue
25.1M
↓ 78.28%
Net Income
-122.9M
↑ 297.53%
Net Profit Margin
-489.71%
↓ 462.95%
FY23Y/Y Change
Revenue
48.7M
↑ 94.15%
Net Income
-69.8M
↓ 43.24%
Net Profit Margin
-143.18%
↑ 346.53%
Q3 FY22Q/Q Change
Revenue
7.4M
↑ 92.75%
Net Income
-25.0M
↓ 23.12%
Net Profit Margin
-339.02%
↑ 510.95%
Q4 FY22Q/Q Change
Revenue
10.6M
↑ 43.94%
Net Income
-36.5M
↑ 46.17%
Net Profit Margin
-344.28%
↓ 5.26%
Q1 FY23Q/Q Change
Revenue
8.8M
↓ 17.15%
Net Income
-23.6M
↓ 35.43%
Net Profit Margin
-268.31%
↑ 75.97%
Q2 FY23Q/Q Change
Revenue
19.8M
↑ 125.39%
Net Income
-11.9M
↓ 49.52%
Net Profit Margin
-60.09%
↑ 208.22%
Q3 FY23Q/Q Change
Revenue
13.1M
↓ 33.7%
Net Income
-8.1M
↓ 32.06%
Net Profit Margin
-61.58%
↓ 1.49%
Q4 FY23Q/Q Change
Revenue
7.0M
↓ 46.36%
Net Income
-16.3M
↑ 101.62%
Net Profit Margin
-231.44%
↓ 169.86%
FY18Y/Y Change
Total Assets
138.6M
↑ 90.69%
Total Liabilities
98.6M
↓ 0.41%
FY19Y/Y Change
Total Assets
235.2M
↑ 69.72%
Total Liabilities
96.9M
↓ 1.74%
FY20Y/Y Change
Total Assets
150.2M
↓ 36.17%
Total Liabilities
105.7M
↑ 9.09%
FY21Y/Y Change
Total Assets
211.5M
↑ 40.85%
Total Liabilities
120.3M
↑ 13.81%
FY22Y/Y Change
Total Assets
238.2M
↑ 12.61%
Total Liabilities
177.7M
↑ 47.71%
FY23Y/Y Change
Total Assets
159.8M
↓ 32.91%
Total Liabilities
140.9M
↓ 20.71%
Q3 FY22Q/Q Change
Total Assets
271.7M
↓ 8.56%
Total Liabilities
187.4M
↓ 3.5%
Q4 FY22Q/Q Change
Total Assets
238.2M
↓ 12.35%
Total Liabilities
177.7M
↓ 5.13%
Q1 FY23Q/Q Change
Total Assets
204.5M
↓ 14.14%
Total Liabilities
164.3M
↓ 7.55%
Q2 FY23Q/Q Change
Total Assets
181.7M
↓ 11.15%
Total Liabilities
147.7M
↓ 10.14%
Q3 FY23Q/Q Change
Total Assets
164.3M
↓ 9.55%
Total Liabilities
135.3M
↓ 8.38%
Q4 FY23Q/Q Change
Total Assets
159.8M
↓ 2.78%
Total Liabilities
140.9M
↑ 4.17%
FY18Y/Y Change
Operating Cash Flow
-51.7M
↑ 114.01%
Investing Cash Flow
-15.7M
↑ 184.01%
Financing Cash Flow
107.8M
↓ 11602.35%
FY19Y/Y Change
Operating Cash Flow
-71.0M
↑ 37.3%
Investing Cash Flow
-24.7M
↑ 57.48%
Financing Cash Flow
173.4M
↑ 60.86%
FY20Y/Y Change
Operating Cash Flow
-87.4M
↑ 23.05%
Investing Cash Flow
-5.0M
↓ 79.6%
Financing Cash Flow
1.3M
↓ 99.23%
FY21Y/Y Change
Operating Cash Flow
-10.9M
↓ 87.58%
Investing Cash Flow
-5.8M
↑ 15.34%
Financing Cash Flow
70.5M
↑ 5206.32%
FY22Y/Y Change
Operating Cash Flow
-45.8M
↑ 321.57%
Investing Cash Flow
-3.3M
↓ 42.81%
Financing Cash Flow
95.0M
↑ 34.69%
Q3 FY22Q/Q Change
Operating Cash Flow
29.2M
↓ 220.48%
Investing Cash Flow
-1.1M
↑ 39.92%
Financing Cash Flow
-180.0K
↓ 100.19%
Q4 FY22Q/Q Change
Operating Cash Flow
-21.8M
↓ 174.84%
Investing Cash Flow
-632.0K
↓ 42.02%
Financing Cash Flow
-5.0K
↓ 97.22%
Q1 FY23Q/Q Change
Operating Cash Flow
-31.5M
↑ 44.05%
Investing Cash Flow
-721.0K
↑ 14.08%
Financing Cash Flow
741.0K
↓ 14920.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-21.1M
↓ 32.83%
Investing Cash Flow
-1.1M
↑ 46.46%
Financing Cash Flow
1.9M
↑ 149.93%

Technicals Summary

Sell

Neutral

Buy

Precision Biosciences Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Precision Biosciences Inc
Precision Biosciences Inc
-1.88%
24.45%
-57.76%
-95.28%
-96.85%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Precision Biosciences Inc
Precision Biosciences Inc
NA
NA
NA
-7.4
-1.07
-0.14
NA
4.53
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Precision Biosciences Inc
Precision Biosciences Inc
Buy
$89.0M
-96.85%
NA
-125.84%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • Capital World Investors

    2.60%

  • Vanguard Group Inc

    2.38%

  • Acadian Asset Management LLC

    1.70%

  • Citadel Advisors Llc

    1.59%

  • Renaissance Technologies Corp

    1.32%

  • Stifel Financial Corp

    0.79%

Corporate Announcements

  • Precision Biosciences Inc Earnings

    Precision Biosciences Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

precision biosciences, inc. is a biotechnology company located in durham, north carolina, united states.

Organization
Precision Biosciences Inc
Employees
109
CEO
Mr. Michael Amoroso
Industry
Biotechnology

Discover More

FAQs